Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
Historique:
pubmed:
11
9
2020
medline:
30
6
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV). Retrospective review of patients (N = 31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant. No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx. With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV. This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.
Sections du résumé
BACKGROUND
It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV).
METHODS
Retrospective review of patients (N = 31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant.
RESULTS
No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx.
DISCUSSION AND CONCLUSIONS
With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV.
SCIENTIFIC SIGNIFICANCE
This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.
Identifiants
pubmed: 32909986
pii: 01271255-202106000-00003
doi: 10.1097/ADM.0000000000000730
doi:
Substances chimiques
Buprenorphine, Naloxone Drug Combination
0
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-190Informations de copyright
Copyright © 2020 American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
The authors have no conflicts of interests to disclose.
Références
Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis a virus infections — United States, 2013-2018. MMWR Morb Mortal Wkly Rep 2019; 68:413–415.
Widespread Person-to-Person Outbreaks of Hepatitis A across the United States. Centers for Disease Control and Prevention, 24 Feb. 2020. Available from: www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.html . Accessed July 18, 2020.
Behan J, Geier M. Intolerance of sublingual buprenorphine-naloxone during induction in a patient with end-stage liver disease: a case report. Ment Health Clin 2016; 6 (3):131–133.
Tetrault JM, Tate JP, Edelman EJ, et al. Hepatic safety of buprenorphine in HIV-infected and uninfected patients with opioid use disorder: the role of HCV-infection. J Subst Abuse Treat 2016; 68:62–67.
Masson CL, Rainey PM, Moody DE, et al. Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals. Am J Addict 2014; 23 (1):34–40.
Nasser AF, Heidbreder C, Liu Y, et al. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (child-pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. Clin Pharmacokinet 2015; 54:837–849.
Koff, Raymond S. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10:S15–S17.
Bruce RD, Altice FL. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse 2007; 33 (6):869–874.
Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis 2012; 31 (1):8–18.